Santhera is scheduled to meet with the FDA in the next few weeks, after which it expects to submit idebenone for approval by the middle of the year.
It's common for drug companies to raise the price of their existing products once or twice per year, every year. The price increases far outpace the rate of inflation.
Gilead Sciences should solve its long-term revenue cliff problem by acquiring Vertex Pharmaceuticals and its growing cystic fibrosis drug franchise for $45 billion, says Bernstein analyst Geoff Porges.
Shares of Juno Therapeutics and Kite Pharma are weak Monday following a lackluster showing for so-called CAR-T cellular therapies in solid tumors at a closely watched cancer conference this weekend.
The positive phase I safety study was conducted using a CAR-T therapy from Novartis and the University of Pennsylvania.
New Keytruda data presented for the first time shows an overall response rate of 19% and a median duration of response exceeding one year in lung cancer patients.
Biotech columnist Adam Feuerstein answers readers' questions about health care.
In which Musk learns how to put a happy spin on failure from biotech CEOs.
Aduro Biotech shares doubled in value Wednesday following a successful initial public offering -- another sign that investor demand for cancer immunotherapy stocks remains strong.
The bull and bear cases for Gilead's first-quarter earnings hinge on discounts applied to prices of hepatitis C drug Harvoni and Sovaldi.